CEO de Moderna describe próximos pasos tras éxito de vacuna contra melanoma

CEO de Moderna describe próximos pasos tras éxito de vacuna contra melanoma

Negocios Salud
Inicia sesión para fijar este evento

El director ejecutivo de Moderna, Stéphane Bancel, declaró en Nueva York que la compañía presentará los resultados de fase 3 de su vacuna de ARNm personalizada contra el melanoma, intismeran, y explicó cómo los datos influirán en la futura dirección de investigación. El ensayo fase 3, realizado conjuntamente con Merck y combinado con Keytruda, mostró una reducción del 42 % en la recurrencia o muerte por melanoma y disminuyó el riesgo de metástasis a distancia en un 38 % frente a Keytruda solo. Los resultados cumplieron las expectativas, aunque las acciones de ambas empresas cayeron tras el anuncio.

Actores

Moderna Merck TD Cowen RBC Capital Markets

Ubicaciones

Wall Street, New York, United States

Verificación de hechos

Cómo funcionan estas métricas
Veredicto general: Parcialmente confirmado Confianza: 72% Afirmaciones: 5
Resumen

One claim stating that a Merck-Moderna mRNA vaccine combined with Keytruda reduced melanoma recurrence or death by 42% in a pivotal study was confirmed. Three claims were partially confirmed: the Moderna-Merck personalized mRNA vaccine intismeran reduced melanoma recurrence and death by 42% when added to Keytruda in a phase III study, Moderna's chief executive Stéphane Bancel noted the upcoming presentation of Phase 3 results for the mRNA melanoma therapy intismeran, and the combined vaccine and Keytruda regimen lowered distant metastasis risk by 38% in patients with resected melanoma. One claim reporting that Merck and Moderna announced on October 22, 2026, that their personalized mRNA vaccine combined with Keytruda reduced the risk of death or recurrence by 42% in patients with resected melanoma had not enough evidence.

Inicia sesión o suscríbete para ver el análisis completo con afirmaciones, fuentes y validación cronológica.

Registrarse Iniciar sesión

Esta sección contiene una verificación automatizada de afirmaciones con fuentes externas y puede incluir imprecisiones.

Artículos

26 de octubre de 2026
2 en total
Moderna CEO on what's next after success in cancer vaccine
Moderna CEO on what's next after success in cancer vaccine

STAT • 26 de oct 08:31

Moderna's chief executive Stéphane Bancel highlighted the upcoming presentation of Phase 3 results for the mRNA melanoma therapy intismeran and outlined its implications for the company's research direction.

Credibilidad 72% Manip. 8% Centro
World-First Cancer Vaccine Cuts Melanoma Recurrence or Death Risk by 42% in Landmark Trial
World-First Cancer Vaccine Cuts Melanoma Recurrence or Death Risk by 42% in Landmark Trial

ScienceAlert • 26 de oct 02:01

A phase 3 study of a personalized mRNA vaccine developed by Moderna and Merck showed a 42% reduction in melanoma recurrence or death compared with standard immunotherapy alone.

Credibilidad 78% Manip. 32% Centro
25 de octubre de 2026
2 en total
Cancer vaccine significantly reduces chance of melanoma patients’ tumours returning, results show
Cancer vaccine significantly reduces chance of melanoma patients’ tumours returning, results show

The Globe and Mail • 25 de oct 18:12

A trial of the mRNA-based vaccine intismeran showed a 42% reduction in melanoma recurrence two years after surgery when added to standard therapy.

Credibilidad 78% Manip. 12% Centro
What's next for cancer vaccines after successful melanoma study
What's next for cancer vaccines after successful melanoma study

STAT • 25 de oct 08:34

A Merck-Moderna mRNA vaccine combined with Keytruda lowered melanoma recurrence or death by 42% in a pivotal study, prompting discussion of broader cancer-vaccine applications.

Credibilidad 73% Manip. 32% Centro
23 de octubre de 2026
1 en total
Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial
Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial

NBC News • 23 de oct 18:42

In a phase III study, the Moderna-Merck personalized mRNA vaccine intismeran reduced melanoma recurrence and death by 42% when added to Keytruda, compared with Keytruda alone.

Credibilidad 71% Manip. 32% Centro
22 de octubre de 2026
2 en total
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results

BioPharma Dive • 22 de oct 22:24

A combined vaccine and Keytruda regimen reduced the relative risk of disease recurrence or death by 42% in advanced melanoma, meeting expectations, while the companies' stocks fell after the announcement.

Credibilidad 71% Manip. 8% Centro
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

Ars Technica • 22 de oct 22:12

Merck and Moderna reported that their personalized mRNA vaccine combined with Keytruda reduced the risk of death or recurrence by 42% in patients with resected melanoma, and lowered distant metastasis risk by 38%.

Credibilidad 78% Manip. 7% Centro

Eventos relacionados